Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1665-1671

  Gage, Julia C ^a   Katki, Hormuzd A ^a   Schiffman, Mark ^a   Fetterman, Barbara ^b   Poitras, Nancy E ^b   Lorey, Thomas ^b   Cheung, Li C ^c   Castle, Philip E ^d   Kinney, Walter K ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d Global Cancer Initiative   (United States)

Author keywords

Age; Cancer prevention; Cervical intraepithelial neoplasia; Cytology; Human Papillomavirus; Hybrid capture 2

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; RISK ASSESSMENT; SCREENING TEST; UTERINE CERVIX CARCINOMA IN SITU; ALPHAPAPILLOMAVIRUS; CANCER GRADING; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT ANALYSIS; COMPLICATION; EARLY CANCER DIAGNOSIS; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PRECANCER; RISK; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR;

ADULT; AGE FACTORS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RISK; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84920939674     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29143     Document Type: Article

References (34)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
5. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Lower Genital Tract Dis 2012;16:175-204.
6. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-16.
7. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008;68:8813-24.
8. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
9. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-96.
10. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684-91.
11. Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009;100:1184-90.
12. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus per-sistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24.
13. Rositch AF, Silver MI, Burke A, et al. The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women. J Lower Genital Tract Dis 2013;17:38-47.
14. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011;121:4593-9.
15. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
16. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 31 risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Lower Genital Tract Dis 2013;17:S28-S35.
17. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J Am Med Assoc 2002;287:2114-9.
18. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUSLSIL Triage Study. J Am Med Assoc 2001;285:1500-5.
19. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007;127:805-15.
20. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18-25.
21. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116:1373-80.
22. Lawless JF. Statistical models and methods for lifetime data, 2nd ed. Hoboken, New Jersey: Wiley-Interscience, 2003. 630 p.
23. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Roy Stat Soc B 1976;38:290-5.
24. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
25. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-6.
26. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
27. Pike MC, Krailo MD, Henderson BE, et al. 'Hormonal' risk factors, 'breast tissue age' and the ageincidence of breast cancer. Nature 1983;303:767-70.
28. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012;130:2638-44.
29. Rositch AF, Burke AE, Viscidi RP, et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012;72:6183-90.
30. Gonzalez P, Hildesheim A, Rodriguez AC, et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010;19:3044-54.
31. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 2007;56:1-24.
32. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009;151:538-45.
33. Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007;57:105-11.
34. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer 2014;120:2032-8.